JP5702396B2 - ベンゾジアゼピンブロモドメイン阻害剤 - Google Patents

ベンゾジアゼピンブロモドメイン阻害剤 Download PDF

Info

Publication number
JP5702396B2
JP5702396B2 JP2012537381A JP2012537381A JP5702396B2 JP 5702396 B2 JP5702396 B2 JP 5702396B2 JP 2012537381 A JP2012537381 A JP 2012537381A JP 2012537381 A JP2012537381 A JP 2012537381A JP 5702396 B2 JP5702396 B2 JP 5702396B2
Authority
JP
Japan
Prior art keywords
methyl
alkyl
compound
chlorophenyl
methyloxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012537381A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013510123A5 (enExample
JP2013510123A (ja
Inventor
ベイリー，ジェイムズ
ゴスミニ，ロマン，リュック，マリー
ミルゲ，オリヴィエ
ウィザーリントン，ジェイソン
Original Assignee
グラクソスミスクライン エルエルシー
グラクソスミスクライン エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0919433A external-priority patent/GB0919433D0/en
Priority claimed from GBGB1010509.6A external-priority patent/GB201010509D0/en
Priority claimed from PCT/EP2010/061518 external-priority patent/WO2011054553A1/en
Priority claimed from GBGB1014231.3A external-priority patent/GB201014231D0/en
Application filed by グラクソスミスクライン エルエルシー, グラクソスミスクライン エルエルシー filed Critical グラクソスミスクライン エルエルシー
Publication of JP2013510123A publication Critical patent/JP2013510123A/ja
Publication of JP2013510123A5 publication Critical patent/JP2013510123A5/ja
Application granted granted Critical
Publication of JP5702396B2 publication Critical patent/JP5702396B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012537381A 2009-11-05 2010-11-03 ベンゾジアゼピンブロモドメイン阻害剤 Expired - Fee Related JP5702396B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB0919433.3 2009-11-05
GB0919433A GB0919433D0 (en) 2009-11-05 2009-11-05 Novel compounds
GBGB1010509.6A GB201010509D0 (en) 2010-06-22 2010-06-22 Novel compounds
GB1010509.6 2010-06-22
PCT/EP2010/061518 WO2011054553A1 (en) 2009-11-05 2010-08-06 Benzodiazepine bromodomain inhibitor
EPPCT/EP2010/061518 2010-08-06
GBGB1014231.3A GB201014231D0 (en) 2010-08-25 2010-08-25 Novel compounds
GB1014231.3 2010-08-25
PCT/EP2010/066697 WO2011054845A1 (en) 2009-11-05 2010-11-03 Benzodiazepine bromodomain inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015030132A Division JP2015143232A (ja) 2009-11-05 2015-02-19 ベンゾジアゼピンブロモドメイン阻害剤

Publications (3)

Publication Number Publication Date
JP2013510123A JP2013510123A (ja) 2013-03-21
JP2013510123A5 JP2013510123A5 (enExample) 2013-11-21
JP5702396B2 true JP5702396B2 (ja) 2015-04-15

Family

ID=43969589

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012537381A Expired - Fee Related JP5702396B2 (ja) 2009-11-05 2010-11-03 ベンゾジアゼピンブロモドメイン阻害剤
JP2015030132A Pending JP2015143232A (ja) 2009-11-05 2015-02-19 ベンゾジアゼピンブロモドメイン阻害剤
JP2016185487A Pending JP2017039738A (ja) 2009-11-05 2016-09-23 ベンゾジアゼピンブロモドメイン阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015030132A Pending JP2015143232A (ja) 2009-11-05 2015-02-19 ベンゾジアゼピンブロモドメイン阻害剤
JP2016185487A Pending JP2017039738A (ja) 2009-11-05 2016-09-23 ベンゾジアゼピンブロモドメイン阻害剤

Country Status (23)

Country Link
US (3) US9102677B2 (enExample)
EP (2) EP3050885B1 (enExample)
JP (3) JP5702396B2 (enExample)
KR (1) KR20120097508A (enExample)
CN (1) CN102781943B (enExample)
AU (1) AU2010317096B2 (enExample)
BR (1) BR112012010705A2 (enExample)
CA (1) CA2779423C (enExample)
CY (1) CY1117424T1 (enExample)
DK (1) DK2496582T3 (enExample)
EA (1) EA023441B1 (enExample)
ES (2) ES2564318T3 (enExample)
HK (1) HK1221221A1 (enExample)
HR (1) HRP20160253T1 (enExample)
HU (1) HUE026967T2 (enExample)
IL (2) IL219253A (enExample)
ME (1) ME02356B (enExample)
MX (1) MX341212B (enExample)
PL (1) PL2496582T3 (enExample)
RS (1) RS54645B1 (enExample)
SI (1) SI2496582T1 (enExample)
SM (1) SMT201600104B (enExample)
WO (1) WO2011054845A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015143232A (ja) * 2009-11-05 2015-08-06 グラクソスミスクライン エルエルシー ベンゾジアゼピンブロモドメイン阻害剤

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008007071A1 (en) 2006-07-10 2008-01-17 Cenes Limited Short-acting benzodiazepine salts and their polymorphic forms
WO2011143657A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Male contraceptive compositions and methods of use
DK2571503T3 (en) 2010-05-14 2015-04-20 Dana Farber Cancer Inst Inc COMPOSITIONS AND THEIR USE IN THE TREATMENT OF NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS
JP5715241B2 (ja) * 2010-05-14 2015-05-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法
WO2011143660A2 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
EP2705039B1 (en) 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012174487A2 (en) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
GB201114103D0 (en) * 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
WO2013033268A2 (en) * 2011-08-29 2013-03-07 Coferon, Inc. Bivalent bromodomain ligands, and methods of using same
DE102011082013A1 (de) 2011-09-01 2013-03-07 Bayer Pharma AG 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
WO2013155695A1 (en) 2012-04-20 2013-10-24 Abbott Laboratories Isoindolone derivatives
BR112014029108B1 (pt) * 2012-05-22 2022-02-08 Paion Uk Limited Composições que compreendem benzodiazepinas de curta ação, uso de uma mistura de pelo menos um dissacarídeo e pelo menos uma dextrana e método de preparação de uma composição farmacêutica
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
WO2013184878A1 (en) 2012-06-06 2013-12-12 Constellation Pharmaceuticals, Inc. Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof
RU2632915C2 (ru) 2012-06-12 2017-10-11 Эббви Инк. Производные пиридинона и пиридазинона
ES2628005T3 (es) 2012-08-16 2017-08-01 Bayer Pharma Aktiengesellschaft 2,3-Benzodiazepinas
AU2013302766B2 (en) * 2012-08-16 2016-10-20 Glaxosmithkline Llc Benzodiazepines for treating small cell lung cancer
JP6276277B2 (ja) * 2012-09-28 2018-02-07 バイエル ファーマ アクチエンゲゼルシャフト Ｂｅｔタンパク質阻害性の５−アリールトリアゾロアゼピン
CN105073744B (zh) 2012-12-21 2019-11-08 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的新型杂环化合物
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
AU2014249192B2 (en) 2013-03-11 2017-12-21 The Regents Of The University Of Michigan BET bromodomain inhibitors and therapeutic methods using the same
JP2016516701A (ja) * 2013-03-11 2016-06-09 アッヴィ・インコーポレイテッド 縮合四環系ブロモドメイン阻害剤
CN108440528A (zh) * 2013-03-12 2018-08-24 艾伯维公司 四环布罗莫结构域抑制剂
WO2014159392A1 (en) 2013-03-14 2014-10-02 Dana-Farber Cancer Institute, Inc. Bromodomain binding reagents and uses thereof
KR20150135359A (ko) * 2013-03-14 2015-12-02 컨버진 엘엘씨 브로모도메인-함유 단백질의 억제를 위한 방법 및 조성물
EA038494B1 (ru) 2013-03-15 2021-09-07 Инсайт Холдингс Корпорейшн Трициклические гетероциклы как ингибиторы белков бэт
EA027139B1 (ru) 2013-04-26 2017-06-30 Бейджин, Лтд. Замещенные 5-(3,5-диметилизоксазол-4-ил)индолин-2-оны
CN103202815B (zh) * 2013-05-05 2014-09-24 李友香 治疗精神疾病的注射剂
CN104146970A (zh) * 2013-05-05 2014-11-19 王元青 治疗精神疾病的冻干粉针剂
WO2015002754A2 (en) 2013-06-21 2015-01-08 Zenith Epigenetics Corp. Novel bicyclic bromodomain inhibitors
US9662311B2 (en) 2013-06-21 2017-05-30 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
US9290514B2 (en) 2013-07-08 2016-03-22 Incyte Holdings Corporation Tricyclic heterocycles as BET protein inhibitors
KR20160034379A (ko) 2013-07-25 2016-03-29 다나-파버 캔서 인스티튜트 인크. 전사 인자의 억제제 및 그의 용도
CA2919948C (en) 2013-07-31 2020-07-21 Zenith Epigenetics Corp. Novel quinazolinones as bromodomain inhibitors
KR20160072261A (ko) 2013-11-08 2016-06-22 다나-파버 캔서 인스티튜트 인크. 브로모도메인 및 엑스트라-말단 (bet) 단백질 저해제를 이용한 암 치료를 위한 조합 요법
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
WO2015081203A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
GB201320994D0 (en) * 2013-11-28 2014-01-15 Univ Dundee Enzyme function probes
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
CA2936256A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
KR20160115953A (ko) 2014-01-31 2016-10-06 다나-파버 캔서 인스티튜트 인크. 디아미노피리미딘 벤젠술폰 유도체 및 그의 용도
EP3099693A4 (en) 2014-01-31 2017-08-16 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
JP6526060B2 (ja) 2014-02-10 2019-06-05 コンサート ファーマシューティカルズ インコーポレイテッド 置換トリアゾロベンゾジアゼピン
WO2015131113A1 (en) 2014-02-28 2015-09-03 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
CN107074861A (zh) 2014-02-28 2017-08-18 密执安大学评议会 作为bet溴结构域抑制剂的9h嘧啶并[4，5‑b]吲哚和相关类似物
PL3129378T3 (pl) 2014-04-09 2020-03-31 Kainos Medicine, Inc. Związki hamujące bromodomenę i zawierająca je kompozycja farmaceutyczna do zapobiegania lub leczenia nowotworu
HRP20200564T1 (hr) 2014-04-23 2020-06-26 Incyte Corporation 1h-pirolo[2,3-c]piridin-7(6h)-oni i pirazolo[3,4-c]piridin-7(6h)-oni kao inhibitori bet proteina
CA2952526A1 (en) * 2014-06-18 2015-12-23 Bayer Pharma Aktiengesellschaft Bet-protein inhibiting 3,4-dihydropyrido[2,3-b]pyrazinones with meta-substituted aromatic amino- or ether groups
LT3157928T (lt) 2014-06-20 2019-05-27 Constellation Pharmaceuticals, Inc. 2-((4s)-6-(4-chlorfenil)-1-metil-4h-benzo[c]iizoksazolo[4,5-e]azepin-4-il)acetamido kristalinės formos
CA2955074A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
BR112017002190A2 (pt) 2014-08-08 2017-11-21 Dana Farber Cancer Inst Inc derivados de di-hidropteridinona e usos dos mesmos
WO2016044130A1 (en) 2014-09-15 2016-03-24 Incyte Corporation Tricyclic heterocycles for use as bet protein inhibitors
CA2960090A1 (en) * 2014-10-02 2016-04-07 Glaxosmithkline Intellectual Property (No.2) Limited Compound
CN107635979A (zh) 2014-10-27 2018-01-26 腾沙治疗公司 溴结构域抑制剂
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
US10179125B2 (en) 2014-12-01 2019-01-15 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
WO2016087936A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Substituted pyridinones as bromodomain inhibitors
WO2016092375A1 (en) 2014-12-11 2016-06-16 Zenith Epigenetics Corp. Substituted heterocycles as bromodomain inhibitors
WO2016097863A1 (en) 2014-12-17 2016-06-23 Zenith Epigenetics Corp. Inhibitors of bromodomains
EP3262045A1 (en) 2015-02-27 2018-01-03 The Regents of The University of Michigan 9h-pyrimido [4,5-b]indoles as bet bromodomain inhibitors
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
AU2016242861B2 (en) 2015-03-31 2020-08-20 Enanta Phamraceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
WO2016171470A1 (en) * 2015-04-21 2016-10-27 Kainos Medicine, Inc. Bromodomain-inhibiting compounds and methods to prevent or treat a cancer
WO2016196065A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Methods and compositions for assessing responsiveness of cancers to bet inhibitors
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
WO2016203335A1 (en) 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
BR112017028178A2 (pt) 2015-06-26 2018-08-28 Tensha Therapeutics Inc tratamento de carcinoma de linha média nut
JP6765622B2 (ja) 2015-07-17 2020-10-07 日本光電工業株式会社 救命支援装置
EP3324977B1 (en) 2015-07-22 2022-07-13 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as rsv inhibitors
JP2018526424A (ja) 2015-09-11 2018-09-13 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド アセトアミドチエノトリアゾロジアゼピンおよびこれらの使用
CA2996974A1 (en) 2015-09-11 2017-03-16 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
AR106520A1 (es) 2015-10-29 2018-01-24 Incyte Corp Forma sólida amorfa de un inhibidor de proteína bet
RU2742035C2 (ru) 2015-11-25 2021-02-01 Дана-Фарбер Кэнсер Инститьют, Инк. Бивалентные ингибиторы бромодоменов и пути их применения
CN106892924B (zh) * 2015-12-17 2021-01-08 四川科伦博泰生物医药股份有限公司 短效苯并二氮*衍生物、其制备方法及其用途
EP3402799B1 (en) 2016-01-15 2022-05-04 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
WO2017142881A1 (en) 2016-02-15 2017-08-24 The Regents Of The University Of Michigan Fused 1,4-oxazepines and related analogs as bet bromodomain inhibitors
CN109415336B (zh) 2016-04-06 2023-08-29 密执安大学评议会 Mdm2蛋白质降解剂
CN109311900A (zh) 2016-04-06 2019-02-05 密执安大学评议会 用于配体依赖性靶蛋白质降解的单官能中间体
EP3442976B1 (en) 2016-04-12 2022-07-20 The Regents of The University of Michigan Bet protein degraders
EP3442972B1 (en) 2016-04-15 2020-03-04 AbbVie Inc. Bromodomain inhibitors
WO2017189652A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10080742B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017189663A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
DE102017005089A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one
DE102017005091A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one
KR102460046B1 (ko) 2016-06-20 2022-10-31 인사이트 코포레이션 Bet 저해제의 결정질 고체 형태
CN107629057B (zh) * 2016-07-19 2020-03-27 上海勋和医药科技有限公司 Bet蛋白抑制剂及其应用
WO2018022802A1 (en) 2016-07-26 2018-02-01 University Of Southern California Selective bromodomain inhibition of fungal bdf1
CA3036834A1 (en) 2016-09-13 2018-03-22 The Regents Of The University Of Michigan Fused 1,4-oxazepines as bet protein degraders
CA3036841A1 (en) 2016-09-13 2018-03-22 The Regents Of The University Of Michigan Fused 1,4-diazepines as bet protein degraders
BR112019006651A2 (pt) 2016-10-04 2019-07-02 Enanta Pharm Inc análogos de isoxazol como agonistas de fxr e métodos de uso do mesmo
WO2018081285A1 (en) 2016-10-26 2018-05-03 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof
RU2019117356A (ru) 2016-11-10 2020-12-10 Лосинь Фармасьютикал (Шанхай) Ко., Лтд. Азотсодержащее макроциклическое соединение, способ его получения, фармацевтическая композиция и применение
WO2018129287A1 (en) * 2017-01-06 2018-07-12 Enanta Pharmaceuticals, Inc. Heteroaryldiazepine derivatives as rsv inhibitors
WO2018144789A1 (en) 2017-02-03 2018-08-09 The Regents Of The University Of Michigan Fused 1,4-diazepines as bet bromodomain inhibitors
EP3582784B1 (en) 2017-02-16 2022-06-08 Enanta Pharmaceuticals, Inc. Processes for the preparation of benzodiazepine derivatives
CN108727380A (zh) * 2017-04-13 2018-11-02 中国科学院上海药物研究所 一种brd4抑制剂及其制备和应用
WO2018196662A1 (zh) * 2017-04-28 2018-11-01 四川科伦博泰生物医药股份有限公司 包含苯并二氮䓬类化合物的注射用组合物及其制备方法
CN108948018B (zh) * 2017-05-17 2021-03-30 四川科伦博泰生物医药股份有限公司 苯并二氮*衍生物及其盐和相关晶体形式、制备方法和用途
WO2018226801A1 (en) 2017-06-07 2018-12-13 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as rsv inhibitors
WO2019006295A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
WO2019006291A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
US11267822B2 (en) 2017-09-13 2022-03-08 The Regents Of The University Of Michigan BET bromodomain protein degraders with cleavable linkers
CA3076759A1 (en) * 2017-09-22 2019-03-28 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Thienodiazepine derivatives and application thereof
CA3077309A1 (en) 2017-09-29 2019-04-04 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as rsv inhibitors
US10647711B2 (en) 2017-11-13 2020-05-12 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as RSV inhibitors
KR102634720B1 (ko) 2017-11-13 2024-02-06 이난타 파마슈티칼스, 인코포레이티드 벤조디아제핀-2-온 및 벤조아제핀-2-온 유도체의 분할 방법
US10689391B2 (en) 2017-12-12 2020-06-23 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
WO2019160813A1 (en) 2018-02-14 2019-08-22 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10975094B2 (en) 2018-04-11 2021-04-13 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
EP3849987B1 (en) * 2018-09-11 2024-04-17 F. Hoffmann-La Roche AG Tert-butyl (s)-2-(4-(phenyl)-6h-thieno[3,2-f][1,2,4]triazolo[4,3-a] [1,4]diazepin-6-yl) acetate derivatives and related compounds as bromodomain brd4 inhibitors for treating cancer
JP7292400B2 (ja) * 2019-03-07 2023-06-16 メッドシャイン ディスカバリー インコーポレイテッド ＢＥＴ Ｂｒｏｍｏｄｏｍａｉｎタンパク質の阻害とＰＤ－Ｌ１遺伝子の調節の両方の効果を持つ化合物
WO2020190935A1 (en) 2019-03-18 2020-09-24 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as rsv inhibitors
US11179400B2 (en) 2019-04-09 2021-11-23 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
US11555032B2 (en) 2019-05-13 2023-01-17 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
AU2020357452A1 (en) 2019-10-04 2022-05-12 Enanta Pharmaceuticals, Inc Antiviral heterocyclic compounds
PT116050B (pt) * 2020-01-09 2022-06-15 Hovione Farm S A Conjugados fármaco-ligando e inibidores das proteínas da família bromodomínio e domínio extraterminal -(bet) modificados
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
WO2021175432A1 (en) 2020-03-04 2021-09-10 Boehringer Ingelheim International Gmbh Method for administration of an anti cancer agent
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
IL299163A (en) 2020-06-23 2023-02-01 Genentech Inc Macrocyclic compounds and methods of using them
US11534439B2 (en) 2020-07-07 2022-12-27 Enanta Pharmaceuticals, Inc. Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors
WO2022086840A1 (en) 2020-10-19 2022-04-28 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
GB202016977D0 (en) 2020-10-26 2020-12-09 In4Derm Ltd Compounds
CN112358483A (zh) * 2020-11-09 2021-02-12 中国药科大学 一类新型苯并二氮*类化合物、其制备方法及其用途
CN114456171A (zh) * 2020-11-09 2022-05-10 中国药科大学 一类用于镇静催眠的苯并二氮䓬类药物、其制备方法及应用
US11945830B2 (en) 2021-02-26 2024-04-02 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
IL309651A (en) 2021-06-29 2024-02-01 Tay Therapeutics Ltd History Pyrolopyridone is useful in the treatment of cancer
AR129003A1 (es) 2022-04-07 2024-07-03 Enanta Pharm Inc Compuestos heterocíclicos antivirales
AU2023255396A1 (en) 2022-04-19 2024-10-24 Nuevolution A/S Compounds active towards bromodomains
WO2023211997A1 (en) 2022-04-27 2023-11-02 Enanta Pharmaceuticals, Inc. Antiviral compounds
EP4558224A1 (en) 2022-07-21 2025-05-28 Tay Therapeutics Limited Pyrroles and imidazoles as bet protein inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1152066A (en) 1980-02-08 1983-08-16 Hoffmann-La Roche Limited Benzodiazepine derivatives
DE3610848A1 (de) * 1986-04-01 1987-10-15 Boehringer Ingelheim Kg Neue 1,4-diazepine
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
WO1993007129A1 (fr) 1991-10-11 1993-04-15 Yoshitomi Pharmaceutical Industries, Ltd. Medicament utilise pour traiter l'osteoporose et compose de diazepine
JPH06128257A (ja) 1992-10-13 1994-05-10 Yoshitomi Pharmaceut Ind Ltd ピリドジアゼピン化合物
WO1995014694A1 (en) 1993-11-22 1995-06-01 Merck & Co., Inc. Benzodiazepines
JP2622673B2 (ja) * 1994-11-18 1997-06-18 日本たばこ産業株式会社 骨粗鬆症治療薬およびトリアゼピン化合物
CA2205173A1 (en) * 1994-11-18 1996-05-30 Takeshi Nakamura Therapeutic agent for osteoporosis and triazepine compound
CA2258053A1 (en) 1996-06-12 1997-12-18 Yoshihisa Yamamoto Cytokine production inhibitors, triazepine compounds, and intermediates thereof
EA001732B1 (ru) 1996-09-13 2001-08-27 Велфайд Корпорейшн Тиенотриазолодиазепиновые соединения и лекарственное средство
JPH11228576A (ja) * 1997-12-10 1999-08-24 Japan Tobacco Inc アポトーシス抑制剤
US6916995B2 (en) 2003-02-25 2005-07-12 Broadcom Corporation Optimization of routing layers and board space requirements for ball grid array package implementations including single and multi-layer routing
CA2544378A1 (en) 2003-11-03 2005-05-19 Glaxo Group Limited A fluid dispensing device
CN1739788A (zh) 2004-03-31 2006-03-01 新加坡国立大学 Trip－br功能的调节和治疗增殖性紊乱的方法
GB0420970D0 (en) 2004-09-21 2004-10-20 Smithkline Beecham Corp Novel triazoloquinoline compounds
JP5159305B2 (ja) 2005-05-30 2013-03-06 田辺三菱製薬株式会社 チエノトリアゾロジアゼピン化合物及びその医薬としての用途
JP2008156311A (ja) 2006-12-26 2008-07-10 Institute Of Physical & Chemical Research Ｂｒｄ２ブロモドメイン結合剤
CA2710740C (en) * 2007-12-28 2016-07-19 Shinji Miyoshi Thienotriazolodiazepine compound as antitumor agent
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
SI2496582T1 (sl) * 2009-11-05 2016-04-29 Glaxosmithkline Llc Corporation Service Company Benzodiazepinski inhibitor bromodomene
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
ME02360B (me) * 2009-11-05 2016-06-20 Glaxosmithkline Llc Inhibitor bromodomena benzodiazepina

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015143232A (ja) * 2009-11-05 2015-08-06 グラクソスミスクライン エルエルシー ベンゾジアゼピンブロモドメイン阻害剤

Also Published As

Publication number Publication date
MX2012005296A (es) 2012-06-19
EP2496582A1 (en) 2012-09-12
RS54645B1 (sr) 2016-08-31
CN102781943A (zh) 2012-11-14
EA023441B1 (ru) 2016-06-30
CN102781943B (zh) 2016-10-05
AU2010317096A1 (en) 2012-05-31
ME02356B (me) 2016-06-20
PL2496582T3 (pl) 2016-08-31
ES2564318T3 (es) 2016-03-21
CY1117424T1 (el) 2017-04-26
US20150299210A1 (en) 2015-10-22
SI2496582T1 (sl) 2016-04-29
SMT201600104B (it) 2016-04-29
US20120252781A1 (en) 2012-10-04
EP2496582B1 (en) 2016-01-27
EA201290184A1 (ru) 2012-12-28
BR112012010705A2 (pt) 2016-03-29
DK2496582T3 (en) 2016-03-21
HUE026967T2 (en) 2016-07-28
IL239625A0 (en) 2015-08-31
ES2654423T3 (es) 2018-02-13
US9598420B2 (en) 2017-03-21
KR20120097508A (ko) 2012-09-04
US20170145021A1 (en) 2017-05-25
US9102677B2 (en) 2015-08-11
AU2010317096B2 (en) 2015-03-26
IL219253A0 (en) 2012-06-28
EP3050885A1 (en) 2016-08-03
CA2779423C (en) 2018-08-14
IL219253A (en) 2015-11-30
HRP20160253T1 (hr) 2016-04-08
IL239625B (en) 2018-05-31
HK1221221A1 (en) 2017-05-26
EP3050885B1 (en) 2017-10-18
JP2015143232A (ja) 2015-08-06
JP2013510123A (ja) 2013-03-21
CA2779423A1 (en) 2011-05-12
WO2011054845A1 (en) 2011-05-12
JP2017039738A (ja) 2017-02-23
MX341212B (es) 2016-08-11

Similar Documents

Publication Publication Date Title
JP5702396B2 (ja) ベンゾジアゼピンブロモドメイン阻害剤
JP5524343B2 (ja) ベンゾジアゼピンブロモドメイン阻害剤
US9085582B2 (en) Benzotriazolodiazepine compounds inhibitors of bromodomains
US20120202799A1 (en) Condensed Azepine Derivatives As Bromodomain Inhibitors
EP2496558A1 (en) Thetrahydroquinolines derivatives as bromodomain inhibitors
AU2015203454B2 (en) Benzodiazepine bromodomain inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131001

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131001

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140909

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150219

R150 Certificate of patent or registration of utility model

Ref document number: 5702396

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees